← Back to Screener
Stereotaxis, Inc. Common Stock (STXS)
Price$1.98
Favorite Metrics
Price vs S&P 500 (26W)-42.62%
Price vs S&P 500 (4W)3.91%
Market Capitalization$197.42M
All Metrics
Book Value / Share (Quarterly)$0.20
P/TBV (Annual)17.46x
Revenue Growth (3Y)4.77%
Cash Flow / Share (Quarterly)$-0.14
Price vs S&P 500 (YTD)-15.88%
Gross Margin (TTM)52.73%
Net Profit Margin (TTM)-66.85%
EPS (TTM)$-0.24
10-Day Avg Trading Volume0.51M
EPS Excl Extra (TTM)$-0.24
Revenue Growth (5Y)3.99%
EPS (Annual)$-0.24
ROI (Annual)-115.61%
Gross Margin (Annual)52.73%
Net Profit Margin (5Y Avg)-65.83%
Cash / Share (Quarterly)$0.14
Revenue Growth QoQ (YoY)36.31%
ROA (Last FY)-41.42%
Revenue Growth TTM (YoY)20.28%
EBITD / Share (TTM)$-0.24
ROE (5Y Avg)-100.98%
Operating Margin (TTM)-69.82%
Cash Flow / Share (Annual)$-0.14
P/B Ratio10.55x
P/B Ratio (Quarterly)11.47x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)5.68x
Net Interest Coverage (TTM)-1071.00x
ROA (TTM)-46.87%
EV / EBITDA (TTM)287.49x
EPS Incl Extra (Annual)$-0.24
Current Ratio (Annual)1.51x
Quick Ratio (Quarterly)1.05x
3-Month Avg Trading Volume0.49M
52-Week Price Return13.41%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.13
P/S Ratio (Annual)6.10x
Asset Turnover (Annual)0.62x
52-Week High$3.59
Operating Margin (5Y Avg)-68.12%
EPS Excl Extra (Annual)$-0.24
CapEx CAGR (5Y)5.85%
Tangible BV CAGR (5Y)28.64%
26-Week Price Return-33.88%
Quick Ratio (Annual)1.05x
13-Week Price Return-26.18%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.51x
Enterprise Value$183.994
Revenue / Share Growth (5Y)-0.55%
Asset Turnover (TTM)0.70x
Book Value / Share Growth (5Y)-18.49%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.71x
Pretax Margin (Annual)-66.85%
Cash / Share (Annual)$0.14
3-Month Return Std Dev47.39%
Gross Margin (5Y Avg)58.88%
Net Income / Employee (TTM)$-0
ROE (Last FY)-115.61%
Net Interest Coverage (Annual)-156.00x
EPS Basic Excl Extra (Annual)$-0.24
P/FCF (TTM)156.18x
Receivables Turnover (TTM)6.70x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.24
Receivables Turnover (Annual)6.70x
ROI (TTM)-191.60%
P/S Ratio (TTM)6.10x
Pretax Margin (5Y Avg)-65.83%
Revenue / Share (Annual)$0.36
Tangible BV / Share (Annual)$0.13
Price vs S&P 500 (52W)-21.69%
Year-to-Date Return-11.74%
5-Day Price Return5.73%
EPS Normalized (Annual)$-0.24
ROA (5Y Avg)-38.82%
Net Profit Margin (Annual)-66.85%
Month-to-Date Return10.33%
Cash Flow / Share (TTM)$-0.26
EBITD / Share (Annual)$-0.24
Operating Margin (Annual)-69.81%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-100.98%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.24
P/TBV (Quarterly)17.46x
P/B Ratio (Annual)11.47x
Inventory Turnover (TTM)1.71x
Pretax Margin (TTM)-66.85%
Book Value / Share (Annual)$0.20
Price vs S&P 500 (13W)-29.05%
Beta1.45x
Revenue / Share (TTM)$0.34
ROE (TTM)-191.60%
52-Week Low$1.69
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.09
4.09
4.09
4.09
Industry Peers — Electromedical Equipment(29)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
STXSStereotaxis, Inc. Common Stock | 6.10x | 3.99% | 52.73% | -69.82% | $1.98 |
MDTMedtronic plc | 3.13x | 3.01% | 65.16% | 17.00% | $85.00 |
MASIMasimo Corporation | 6.11x | 5.95% | 61.90% | 20.30% | $178.45 |
TMDXTransMedics Group, Inc. Common Stock | 6.56x | 88.21% | 59.92% | 17.93% | $113.13 |
LIVNLivaNova PLC Ordinary Shares | 2.59x | 8.24% | 68.04% | 14.09% | $65.81 |
ITGRInteger Holdings Corporation | 1.66x | 11.55% | 27.39% | 11.90% | $89.32 |
AXGNAxogen, Inc. Common Stock | 8.90x | 14.93% | 74.31% | -3.49% | $37.23 |
CNMDCONMED Corporation | 0.88x | 9.77% | 54.59% | 7.46% | $39.68 |
BLFSBioLife Solutions Inc. | 10.84x | 14.87% | 64.56% | -17.26% | $22.19 |
INMDInMode Ltd. Ordinary Shares | 2.51x | 12.45% | 78.54% | 23.05% | $14.57 |
CBLLCeriBell, Inc. Common Stock | 8.96x | — | 87.89% | -65.57% | $21.13 |
About
Stereotaxis Inc specializes in robotic technologies for cardiac arrhythmia treatment and endovascular procedures, providing interventional labs with precision surgical systems and integrated procedural information solutions. The company generates revenue primarily through disposables and service, supplemented by systems sales, royalties, and facility subleases.